183 related articles for article (PubMed ID: 28511060)
21. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.
Becker JP; Weiss J; Theile D
Toxicol Lett; 2014 Feb; 225(1):43-7. PubMed ID: 24275384
[TBL] [Abstract][Full Text] [Related]
22. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate.
Bouvet D; Michalowicz A; Crauste-Manciet S; Brossard D; Provost K
Inorg Chem; 2006 Apr; 45(8):3393-8. PubMed ID: 16602799
[TBL] [Abstract][Full Text] [Related]
23. Raman and Infrared Studies of Platinum-Based Drugs: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, and Heptaplatin.
Torres M; Khan S; Duplanty M; Lozano HC; Morris TJ; Nguyen T; Rostovtsev YV; DeYonker NJ; Mirsaleh-Kohan N
J Phys Chem A; 2018 Aug; 122(34):6934-6952. PubMed ID: 30071735
[TBL] [Abstract][Full Text] [Related]
24. Formation, structure, and dissociation of the ribonuclease S three-dimensional domain-swapped dimer.
López-Alonso JP; Bruix M; Font J; Ribó M; Vilanova M; Rico M; Gotte G; Libonati M; González C; Laurents DV
J Biol Chem; 2006 Apr; 281(14):9400-6. PubMed ID: 16415350
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
26. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of low-energy electrons.
Rezaee M; Hunting DJ; Sanche L
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):847-53. PubMed ID: 23910707
[TBL] [Abstract][Full Text] [Related]
27. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
28. Differences in binding kinetics, bond strength and adduct formation between Pt-based drugs and S- or N-donor groups: A comparative study using mass spectrometry techniques.
Artiaga G; Iglesias-Jiménez A; Moreno-Gordaliza E; Mena ML; Gómez-Gómez MM
Eur J Pharm Sci; 2019 Apr; 132():96-105. PubMed ID: 30844436
[TBL] [Abstract][Full Text] [Related]
29. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?
Lokich J
Cancer Invest; 2001; 19(7):756-60. PubMed ID: 11577818
[No Abstract] [Full Text] [Related]
30. 9,9-Difluorobispidine Analogues of Cisplatin, Carboplatin, and Oxaliplatin.
Mitra R; Goddard R; Pörschke KR
Inorg Chem; 2017 Jun; 56(11):6712-6724. PubMed ID: 28497971
[TBL] [Abstract][Full Text] [Related]
31. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory.
Kato R; Sato T; Iwamoto A; Yamazaki T; Nakashiro S; Yoshikai S; Fujimoto A; Imano H; Ijiri Y; Mino Y; Chikuma M; Tanaka K; Hayashi T
Biopharm Drug Dispos; 2019 Jul; 40(7):242-249. PubMed ID: 31219617
[TBL] [Abstract][Full Text] [Related]
32. Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers.
Fong CW
Free Radic Biol Med; 2016 Oct; 99():99-109. PubMed ID: 27417937
[TBL] [Abstract][Full Text] [Related]
33. Extensive deamidation of RNase A inhibits its oligomerization through 3D domain swapping.
Fagagnini A; Montioli R; Caloiu A; Ribó M; Laurents DV; Gotte G
Biochim Biophys Acta Proteins Proteom; 2017 Jan; 1865(1):76-87. PubMed ID: 27783927
[TBL] [Abstract][Full Text] [Related]
34. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
35. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
Kasparkova J; Vojtiskova M; Natile G; Brabec V
Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
37. The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme.
Messori L; Marzo T; Merlino A
Chem Commun (Camb); 2014 Aug; 50(61):8360-2. PubMed ID: 24943911
[TBL] [Abstract][Full Text] [Related]
38. Oligomerization of bovine ribonuclease A: structural and functional features of its multimers.
Libonati M; Gotte G
Biochem J; 2004 Jun; 380(Pt 2):311-27. PubMed ID: 15104538
[TBL] [Abstract][Full Text] [Related]
39. Cellular and molecular aspects of drugs of the future: oxaliplatin.
Di Francesco AM; Ruggiero A; Riccardi R
Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
[TBL] [Abstract][Full Text] [Related]
40. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
